OBJECTIVES: Chronic granulomatous disease is a rare phagocyte disorder characterized by an increased susceptibility to infections and inflammatory complications. We describe two patients with chronic granulomatous disease (CGD) complicated by macrophage activation syndrome (MAS) (secondary hemophagocytic lymphohistiocytosis) treated with intravenous immunoglobulin (IVIG). METHODS: A report of two cases of CGD complicated by MAS who were successfully treated with IVIG was made, and a comparison was made with ten other cases reported in the literature. RESULTS: MAS is a severe potentially fatal complication of CGD. Most cases are associated with Burkholderia cepacia and leishmaniasis infection. The treatment of these patients varies between centers, and one example is the use of the HLH-2004 protocol. IVIG could be an effective first line option for this complication in CGD patients. CONCLUSIONS: The exaggerated inflammatory response characteristic of CGD patients could play a role in the development of this complication. IVIG appears to be a safe and effective first line treatment in these patients.
OBJECTIVES:Chronic granulomatous disease is a rare phagocyte disorder characterized by an increased susceptibility to infections and inflammatory complications. We describe two patients with chronic granulomatous disease (CGD) complicated by macrophage activation syndrome (MAS) (secondary hemophagocytic lymphohistiocytosis) treated with intravenous immunoglobulin (IVIG). METHODS: A report of two cases of CGD complicated by MAS who were successfully treated with IVIG was made, and a comparison was made with ten other cases reported in the literature. RESULTS: MAS is a severe potentially fatal complication of CGD. Most cases are associated with Burkholderia cepacia and leishmaniasis infection. The treatment of these patients varies between centers, and one example is the use of the HLH-2004 protocol. IVIG could be an effective first line option for this complication in CGDpatients. CONCLUSIONS: The exaggerated inflammatory response characteristic of CGDpatients could play a role in the development of this complication. IVIG appears to be a safe and effective first line treatment in these patients.
Authors: Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka Journal: Pediatr Blood Cancer Date: 2007-02 Impact factor: 3.167
Authors: Alexandra F Freeman; Beatriz E Marciano; Victoria L Anderson; Gulbu Uzel; Christ Costas; Steven M Holland Journal: Pediatr Infect Dis J Date: 2011-09 Impact factor: 2.129
Authors: Joris M van Montfrans; Eva Rudd; Lisette van de Corput; Jan-Inge Henter; Peter Nikkels; Nico Wulffraat; Jaap J Boelens Journal: Pediatr Blood Cancer Date: 2009-04 Impact factor: 3.167
Authors: Andrea Martín; Laura Marques; Pere Soler-Palacín; Isabel Caragol; Manuel Hernandez; Concepcion Figueras; Teresa Español Journal: Pediatr Infect Dis J Date: 2009-08 Impact factor: 2.129
Authors: Sebastian Fn Bode; Sandra Ammann; Waleed Al-Herz; Mihaela Bataneant; Christopher C Dvorak; Stephan Gehring; Andrew Gennery; Kimberly C Gilmour; Luis I Gonzalez-Granado; Ute Groß-Wieltsch; Marianne Ifversen; Jenny Lingman-Framme; Susanne Matthes-Martin; Rolf Mesters; Isabelle Meyts; Joris M van Montfrans; Jana Pachlopnik Schmid; Sung-Yun Pai; Pere Soler-Palacin; Uta Schuermann; Volker Schuster; Markus G Seidel; Carsten Speckmann; Polina Stepensky; Karl-Walter Sykora; Bianca Tesi; Thomas Vraetz; Catherine Waruiru; Yenan T Bryceson; Despina Moshous; Kai Lehmberg; Michael B Jordan; Stephan Ehl Journal: Haematologica Date: 2015-05-28 Impact factor: 9.941
Authors: Amit Rawat; Surjit Singh; Deepti Suri; Anju Gupta; Biman Saikia; Ranjana Walker Minz; Shobha Sehgal; Kim Vaiphei; C Kamae; K Honma; N Nakagawa; K Imai; S Nonoyama; K Oshima; N Mitsuiki; O Ohara; Koon-Wing Chan; Yu Lung Lau Journal: J Clin Immunol Date: 2013-11-26 Impact factor: 8.317